Anthem Capital Management

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on innovative and long-term implantable glucose monitoring solutions that utilize advanced fluorescence sensing technology. Its flagship products, Eversense and Eversense XL, are implantable CGM systems designed to monitor glucose levels for up to 90 and 180 days, respectively. These products aim to provide users with a reliable and stable means of glucose management, enhancing their ability to live confidently and manage their diabetes effectively. The majority of Senseonics' revenue comes from international markets, reflecting its strong presence in Europe.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Echo360, Inc. is a developer of a Software-as-a-Service learning and analytics platform tailored for higher education institutions both in the United States and internationally. Founded in 2007 and headquartered in Virginia, the company offers a comprehensive solution that enables users to capture, share, and enhance classroom experiences through features such as polls, quizzes, and instructional video recordings. Its platform facilitates connections between students and instructors worldwide and provides learning analytics to identify student engagement levels and potential challenges before exams. Additionally, Echo360 includes a learning library for storing educational materials, universal capture software for recording content on various devices, and an automatic speech recognition solution to support video-based learning. The company aims to transform educational experiences by leveraging active learning technology and interactive software to engage students effectively.

Siperian is a provider of master data management solutions that help companies unify fragmented data about critical business entities, including customers, products, and organizations. The company's MDM Hub™ offers a flexible, integrated software platform designed to adapt to specific business requirements, facilitating effective management of master data and delivering a rapid return on investment for enterprises. Siperian's approach supports a variety of business processes, enhancing customer relationship management, regulatory compliance, and operational efficiency for clients in diverse sectors such as financial services, healthcare, manufacturing, and technology. The company's solutions are supported by a network of partners, including systems integrators and technology providers. Siperian has established a strong reputation in the industry, with Fortune 500 clients like Pfizer and Deutsche Bank relying on its capabilities to address their master data management needs and support both analytical and transactional functions.

RedLasso is a web-based video sharing platform that enables users to search for and create clips from licensed TV and radio broadcasts. The service allows individuals and organizations to easily access professional broadcast news video content and share selected clips online. Founded with the goal of enhancing the accessibility of broadcast media, RedLasso faced legal challenges early in its operation, prompting the company to enlist Michael Jordan, a former CEO of CBS, as a senior advisor. This strategic move aimed to navigate the complexities of media rights while maintaining the platform's functionality and user engagement.

Defywire, Inc. develops wireless connections between teachers, administrators, students, and parents. The company offers Mobile Guardian, a web-based administration console that allows centralized management of mobile users, applications, and school configuration information. Its Mobile Guardian provides access to critical information, reconnecting through cellular, wireless fidelity, satellite, LAN or WAN, or other communication protocols, as well as supports blackberry and various Windows mobile devices, XP desktops, notebooks, and tablet PC's. The company was founded in 2003 and is based in Reston, Virginia.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Qovia is a company that specializes in voice over Internet Protocol (VoIP) telephony monitoring and management technologies. Founded in 2002 and based in Frederick, Maryland, Qovia develops software products designed to monitor and manage voice quality on VoIP telephone systems. Its solutions cater to a diverse range of customers, including school districts, government agencies, law enforcement, banking and financial institutions, call centers, and voice carriers. By leveraging internet technology to enhance voice communication, Qovia positions itself at the forefront of next-generation phone systems.

Triumfant is a provider of advanced endpoint security software that offers continuous protection against sophisticated malware threats. The company's innovative technology enables users to detect, analyze, and swiftly resolve cyberattacks that evade conventional signature-based defenses. Triumfant's system is designed to stop breaches before they escalate into significant incidents, ensuring that no attacker can extract proprietary information or inflict damage on enterprise systems. It features enhanced detection capabilities, including advanced memory and Mac functionalities, minimizing collateral damage and safeguarding critical assets. In the event of an attack, Triumfant automatically repairs affected machines within minutes without the need for human intervention or system downtime, allowing companies and government agencies to quickly recover and prevent potential losses.

Immune Control, Inc. is a biotechnology company established in 2001, focusing on the development of serotonin-based immunotherapeutics aimed at addressing autoimmune conditions and hematologic cancers. Founded on research from Drexel University College of Medicine, the company is working on small molecules that modulate the immune system by targeting serotonin receptors on immune cells. These therapeutics aim to selectively block activated immune cells, offering a more favorable side effect profile compared to traditional treatments. Immune Control's pipeline includes compounds intended for use in conditions such as multiple myeloma, type I diabetes, rheumatoid arthritis, lupus, asthma, and muscular dystrophies, with the potential market for these diseases exceeding a billion dollars. The company is actively advancing its research and has a robust intellectual property portfolio, which includes novel applications and compounds licensed exclusively from Drexel University. The company aims to submit an investigational new drug application to the FDA to initiate clinical trials, with the goal of proving the clinical efficacy of its therapies against various diseases associated with inappropriate lymphocyte activation.

Defywire, Inc. develops wireless connections between teachers, administrators, students, and parents. The company offers Mobile Guardian, a web-based administration console that allows centralized management of mobile users, applications, and school configuration information. Its Mobile Guardian provides access to critical information, reconnecting through cellular, wireless fidelity, satellite, LAN or WAN, or other communication protocols, as well as supports blackberry and various Windows mobile devices, XP desktops, notebooks, and tablet PC's. The company was founded in 2003 and is based in Reston, Virginia.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Nucleonics is a biotechnology company focused on RNA interference-based therapeutics.

Qovia is a company that specializes in voice over Internet Protocol (VoIP) telephony monitoring and management technologies. Founded in 2002 and based in Frederick, Maryland, Qovia develops software products designed to monitor and manage voice quality on VoIP telephone systems. Its solutions cater to a diverse range of customers, including school districts, government agencies, law enforcement, banking and financial institutions, call centers, and voice carriers. By leveraging internet technology to enhance voice communication, Qovia positions itself at the forefront of next-generation phone systems.

BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.

Qovia is a company that specializes in voice over Internet Protocol (VoIP) telephony monitoring and management technologies. Founded in 2002 and based in Frederick, Maryland, Qovia develops software products designed to monitor and manage voice quality on VoIP telephone systems. Its solutions cater to a diverse range of customers, including school districts, government agencies, law enforcement, banking and financial institutions, call centers, and voice carriers. By leveraging internet technology to enhance voice communication, Qovia positions itself at the forefront of next-generation phone systems.

Defywire, Inc. develops wireless connections between teachers, administrators, students, and parents. The company offers Mobile Guardian, a web-based administration console that allows centralized management of mobile users, applications, and school configuration information. Its Mobile Guardian provides access to critical information, reconnecting through cellular, wireless fidelity, satellite, LAN or WAN, or other communication protocols, as well as supports blackberry and various Windows mobile devices, XP desktops, notebooks, and tablet PC's. The company was founded in 2003 and is based in Reston, Virginia.

GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.

Siperian is a provider of master data management solutions that help companies unify fragmented data about critical business entities, including customers, products, and organizations. The company's MDM Hub™ offers a flexible, integrated software platform designed to adapt to specific business requirements, facilitating effective management of master data and delivering a rapid return on investment for enterprises. Siperian's approach supports a variety of business processes, enhancing customer relationship management, regulatory compliance, and operational efficiency for clients in diverse sectors such as financial services, healthcare, manufacturing, and technology. The company's solutions are supported by a network of partners, including systems integrators and technology providers. Siperian has established a strong reputation in the industry, with Fortune 500 clients like Pfizer and Deutsche Bank relying on its capabilities to address their master data management needs and support both analytical and transactional functions.

ScoreBoard, Inc. offers innovative software and services designed to support mobile operators worldwide in optimizing their telecommunications networks. By collecting and analyzing measured network data, ScoreBoard enables carriers to conduct "what if" scenarios that enhance network performance, reliability, and capacity. In light of current challenges such as limited resources, stringent capital markets, and rising consumer demands, ScoreBoard's solutions empower mobile operators to fulfill their commitments to investors and customers effectively.

Highway to Health, (HTH) applies its dynamic Internet expertise to bring innovative online healthcare services and insurance to international travel, study, and commerce. Each year thousands of leisure and business travelers as well as international students and scholars protect themselves, their families, and their travel plans with HTH. Their programs combine comprehensive, competitively priced insurance products with critical travel health information, known as CityHealthProfiles, and online medical assistance services available through HTH TravelersClub. Members enjoy access to their community of pre-selected, contracted physicians in over 100 countries, and their interactive translation guides for brand-name pharmaceuticals and common medical terms and phrases.

ScoreBoard, Inc. offers innovative software and services designed to support mobile operators worldwide in optimizing their telecommunications networks. By collecting and analyzing measured network data, ScoreBoard enables carriers to conduct "what if" scenarios that enhance network performance, reliability, and capacity. In light of current challenges such as limited resources, stringent capital markets, and rising consumer demands, ScoreBoard's solutions empower mobile operators to fulfill their commitments to investors and customers effectively.

Message Pharmaceuticals is a company that provides Communications systems and more.